Patient Safety@ Boehringer Ingelheim Pharmacovigilance

Patient safety is of utmost importance to Boehringer Ingelheim. To achieve this ultimate goal we actively monitor the safety and the benefit-risk profile of all Boehringer Ingelheim products on an ongoing basis through clinical trials, non-interventional observational studies, and spontaneous reports. 

Hundreds of employees working at the Pharmacovigilance department across the globe are registering Adverse Events and other product safety information reported to Boehringer Ingelheim and evaluating all relevant data.
This monitoring starts during the development phase of new Boehringer Ingelheim products and continues when the products are on the market. 

This way, we can ensure an appropriate and beneficial use of Boehringer Ingelheim products while minimizing the impact of product risks on patients’ health and well-being.

In addition, we support Patient Safety internationally as a member of the cooperating organizations of the annual International Patient Safety Day.